Importance Updated estimates of non–small cell lung cancer (NSCLC) in the US are
needed. Objective To calculate the most recent epidemiologic estimates of NSCLC in the …

Importance Over the past 10 years, treatment of non–small cell lung cancer (NSCLC) has
been continually revolutionized. However, standard clinical trials may not reflect current …

Background Lung cancer is made up of distinct subtypes, including non–small-cell lung
cancer (NSCLC) and small-cell lung cancer (SCLC). Although overall mortality from lung …

Purpose Dissemination of recommended therapies for non–small-cell lung cancer (NSCLC)
have not been described comprehensively. We report the patterns of initial therapy focusing …

Lung cancer is the leading cause of cancer mortality worldwide with 1.8 million newly
diagnosed cases, or 13% of all cancers diagnosed, in 2012 [1]. The worldwide numbers are …

Background Although there has been a significant survival improvement for patients with
metastatic NSCLC enrolled in randomized trials, it is not clear whether a similar benefit is …

Lung cancer is the leading cause of cancer death in the United States in both men and
women. An estimated 226,160 new cases will be diagnosed in 2012, and 160,340 deaths …

Importance Early detection by computed tomography and a more attention-oriented
approach to incidentally identified pulmonary nodules in the last decade has led to …

Background Standard therapy for metastatic non small cell lung cancer (NSCLC) includes
palliative systemic chemotherapy and/or radiotherapy. Recent studies of patients with limited …

Background The purpose of this population-based study is to provide a detailed analysis of
survival outcome of patients with stage IIIB and IV non-small cell lung cancer (NSCLC) …